Literature DB >> 17324113

Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.

Xue Zhang1, Robert B Diasio.   

Abstract

Dihydropyrimidine dehydrogenase is the enzyme that is critical for the efficacy and toxicity of the anticancer reagent 5-fluorouracil. It has been demonstrated that the regulation of the dihydropyrimidine dehydrogenase gene has an important role in the determination of the enzyme activity of dihydropyrimidine dehydrogenase. The regulation of the gene expression is thus discussed from two aspects: normal regulation by specificity proteins, and the epigenetic regulation by promoter methylation. The influence of the polymorphism on dihydropyrimidine dehydrogenase enzyme activity and other factors that have been suggested to be involved in dihydropyrimidine dehydrogenase regulation are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324113     DOI: 10.2217/14622416.8.3.257

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  9 in total

Review 1.  Treatment recommendations for metastatic colorectal cancer.

Authors:  Enrique Aranda; Albert Abad; Alfredo Carrato; Andrés Cervantes; Jesús García-Foncillas; Pilar García Alfonso; Rocío García Carbonero; Auxiliadora Gómez España; Josep M Tabernero; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

2.  Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Raoul C M Hennekam; Jan M N Hoovers; Christine E M de Die-Smulders; Peter Weber; Andrea Capone Mori; Jörgen Bierau; Brian Fowler; Klaus Macke; Jörn Oliver Sass; Rutger Meinsma; Julia B Hennermann; Peter Miny; Lida Zoetekouw; Raymon Vijzelaar; Joost Nicolai; Bauke Ylstra; M Estela Rubio-Gozalbo
Journal:  Hum Genet       Date:  2009-03-19       Impact factor: 4.132

3.  Identification of novel germline polymorphisms governing capecitabine sensitivity.

Authors:  Peter H O'Donnell; Amy L Stark; Eric R Gamazon; Heather E Wheeler; Bridget E McIlwee; Lidija Gorsic; Hae Kyung Im; R Stephanie Huang; Nancy J Cox; M Eileen Dolan
Journal:  Cancer       Date:  2012-01-03       Impact factor: 6.860

Review 4.  Exploring the link between chronobiology and drug delivery: effects on cancer therapy.

Authors:  Tânia Albuquerque; Ana R Neves; Telma Quintela; Diana Costa
Journal:  J Mol Med (Berl)       Date:  2021-07-02       Impact factor: 4.599

5.  Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.

Authors:  Sumit Parmar; Julia Carolin Stingl; Ariana Huber-Wechselberger; Alexander Kainz; Wilfried Renner; Uwe Langsenlehner; Peter Krippl; Jürgen Brockmöller; Elisabeth Haschke-Becher
Journal:  Breast Cancer Res       Date:  2011-06-09       Impact factor: 6.466

6.  Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.

Authors:  Christina Leah B Kline; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-21

Review 7.  Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.

Authors:  Laura Grumetti; Rita Lombardi; Federica Iannelli; Biagio Pucci; Antonio Avallone; Elena Di Gennaro; Alfredo Budillon
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

Review 8.  Chronopharmacology: new insights and therapeutic implications.

Authors:  Robert Dallmann; Steven A Brown; Frédéric Gachon
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-16       Impact factor: 13.820

9.  Chronotherapy: Intuitive, Sound, Founded…But Not Broadly Applied.

Authors:  Julia M Selfridge; Tetsuya Gotoh; Samuel Schiffhauer; JingJing Liu; Philip E Stauffer; Andrew Li; Daniel G S Capelluto; Carla V Finkielstein
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.